Dan Coatsworth, head of markets at AJ Bell, said: “There is a lot going right for AstraZeneca.
“Existing products are selling well, there is positive news on drug trials, it continues to make strategic acquisitions and partnerships, and the share price is humming along nicely.
“All big pharma companies strive to have a vibrant pipeline of drugs in development as these are the key to tomorrow’s revenue growth.
“AstraZeneca has an important year ahead with more than 20 final-phase trial results scheduled.
“It’s rare for a company to get a positive result with every single trial, so the goal is to have more successes than failures.
“If AstraZeneca knocks it out of the park with its current pipeline of final-stage trials, it could stand head and shoulders above the peer group.”
Contact details are available to account holders.
Create a free account to get in touch with this expert.